BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 18158969)

  • 1. Acute renal failure after nonmyeloablative stem cell transplantation in adults.
    Kersting S; Dorp SV; Theobald M; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):125-31. PubMed ID: 18158969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early renal injury after nonmyeloablative allogeneic peripheral blood stem cell transplantation in patients with chronic myelocytic leukemia.
    Liu H; Ding JH; Liu BC; Zhao G; Chen BA
    Am J Nephrol; 2007; 27(4):336-41. PubMed ID: 17519537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute renal failure after allogeneic myeloablative stem cell transplantation: retrospective analysis of incidence, risk factors and survival.
    Kersting S; Koomans HA; Hené RJ; Verdonck LF
    Bone Marrow Transplant; 2007 Mar; 39(6):359-65. PubMed ID: 17342159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic kidney disease after nonmyeloablative stem cell transplantation in adults.
    Kersting S; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Apr; 14(4):403-8. PubMed ID: 18342782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic kidney disease after myeloablative allogeneic hematopoietic stem cell transplantation.
    Kersting S; Hené RJ; Koomans HA; Verdonck LF
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1169-75. PubMed ID: 17889353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Willems E; Humblet-Baron S; Dengis O; Seidel L; Beguin Y; Baron F
    Bone Marrow Transplant; 2010 Sep; 45(9):1442-8. PubMed ID: 20062090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Excellent outcome of allogeneic hematopoietic stem cell transplantation using a conditioning regimen with medium-dose VP-16, cyclophosphamide and total-body irradiation for adult patients with acute lymphoblastic leukemia.
    Shigematsu A; Kondo T; Yamamoto S; Sugita J; Onozawa M; Kahata K; Endo T; Shiratori S; Ota S; Obara M; Wakasa K; Takahata M; Takeda Y; Tanaka J; Hashino S; Nishio M; Koike T; Asaka M; Imamura M
    Biol Blood Marrow Transplant; 2008 May; 14(5):568-75. PubMed ID: 18410899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High incidence of invasive aspergillosis associated with intestinal graft-versus-host disease following nonmyeloablative transplantation.
    Labbé AC; Su SH; Laverdière M; Pépin J; Patiño C; Cohen S; Kiss T; Lachance S; Sauvageau G; Busque L; Roy DC; Roy J
    Biol Blood Marrow Transplant; 2007 Oct; 13(10):1192-200. PubMed ID: 17889356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term outcome after bone marrow transplantation for aplastic anemia using cyclophosphamide and total lymphoid irradiation as conditioning regimen.
    Inamoto Y; Suzuki R; Kuwatsuka Y; Yasuda T; Takahashi T; Tsujimura A; Sugimoto K; Oba T; Terakura S; Atsuta Y; Murata M; Ito M; Kodera Y; Miyamura K
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):43-9. PubMed ID: 18158960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years.
    Huisman C; Meijer E; Petersen EJ; Lokhorst HM; Verdonck LF
    Biol Blood Marrow Transplant; 2008 Feb; 14(2):181-6. PubMed ID: 18215778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter, retrospective study of acute kidney injury in adult patients with nonmyeloablative hematopoietic SCT.
    Liu H; Li YF; Liu BC; Ding JH; Chen BA; Xu WL; Qian J
    Bone Marrow Transplant; 2010 Jan; 45(1):153-8. PubMed ID: 19430501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute renal failure after myeloablative allogeneic hematopoietic stem cell transplantation: incidence, risk factors, and relationship with the quantity of transplanted cells.
    Tokgoz B; Kocyigit I; Polat G; Eser B; Unal A; Kaynar L; Sipahioglu MH; Oymak O; Utas C; Cetin M
    Ren Fail; 2010 Jun; 32(5):547-54. PubMed ID: 20486836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and outcomes of acute renal failure following thoracic aortic stent-graft placement.
    Eggebrecht H; Breuckmann F; Martini S; Baumgart D; Herold U; Kienbaum P; Peters J; Jakob H; Erbel R; Mehta RH
    Am J Cardiol; 2006 Aug; 98(4):458-63. PubMed ID: 16893697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical study on acute kidney injury after myeloablative allogeneic hematopoietic cell transplantation].
    Bao YS; Jiang EL; Wang M; Huang Y; Wei JL; Yang DL; Feng SZ; Han MZ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):401-4. PubMed ID: 19031744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of donor graft failure with nonmyeloablative conditioning of fludarabine, antithymocyte globulin and a second allogeneic hematopoietic transplantation.
    Jabbour E; Rondon G; Anderlini P; Giralt SA; Couriel DR; Champlin RE; Khouri IF
    Bone Marrow Transplant; 2007 Sep; 40(5):431-5. PubMed ID: 17603511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation.
    Fuji S; Kim SW; Fukuda T; Mori S; Yamasaki S; Morita-Hoshi Y; Ohara-Waki F; Heike Y; Tobinai K; Tanosaki R; Takaue Y
    Biol Blood Marrow Transplant; 2008 May; 14(5):510-7. PubMed ID: 18410893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.